Table 3.
Distribution of patients in relation to the target range of linezolid
| |
Number (percentage) of linezolid patients |
|||||
|---|---|---|---|---|---|---|
| Patient groups, number of patients |
AUC
24
, mg*h/L
a
|
C
min
, mg/L
b
|
||||
| <200 | 200 to 400 | >400 | <2 | 2 to 10 | >10 | |
| Total patients, n =30 |
19 (63) |
9 (30) |
2 (7) |
15 (50) |
13 (43) |
2 (7) |
| Male patients, n = 20c |
13 (65) |
5 (25) |
2 (10) |
11 (55) |
7 (35) |
2 (10) |
| Female patients, n = 10 |
6 (60) |
4 (40) |
|
4 (40) |
6 (60) |
|
| On CRRT, n = 5d |
2 (40) |
1 (20) |
2 (40) |
|
3 (60) |
2 (40) |
| Not on CRRT, n = 25 |
17 (68) |
8 (32) |
|
15 (60) |
10 (40) |
|
| On ECLA, n = 7c |
5 (71) |
2 (29) |
|
5 (71) |
2 (29) |
|
| Not on ECLA, n = 23 |
14 (61) |
7 (30) |
2 (9) |
10 (43) |
11 (48) |
2 (9) |
| After liver transplantation, n = 5f |
2 (40) |
1 (20) |
2 (40) |
|
3 (60) |
2 (40) |
| After lung transplantation, n = 10c |
6 (60) |
4 (40) |
|
6 (60) |
4 (40) |
|
| No transplantation, n = 15 | 11 (73) | 4 (27) | 9 (60) | 6 (40) | ||
aAs determined by the NONMEM system, values from the start of the third administration of linezolid; bas determined by liquid chromatography tandem mass spectrometry, values obtained directly before the fourth administration of linezolid; cno significantly different values in comparison to the corresponding patient group; dsignificantly higher values in patients on CRRT than in those not on CRRT (P <0.01); fsignificantly higher values in patients with liver transplantation than in non-liver-transplant patients (P <0.05). AUC24, concentration time curve over 24 h; Cmin, linezolid trough level; CRRT, continuous renal replacement therapy; ECLA, extracorporeal lung assist.